PA-915
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H17ClN6O2 |
| Molar mass | 372.81 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PA-915 is a drug used in scientific research which acts as a selective antagonist of the pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1). In animal studies it has been found to prevent the development of allodynia and shows analgesic effects against neuropathic pain,[1] and also shows antidepressant effects.[2]
See also
References
- ^ Takasaki I, Ogashi H, Okada T, Shimodaira A, Hayakawa D, Watanabe A, et al. (January 2020). "Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain". European Journal of Medicinal Chemistry. 186 111902. doi:10.1016/j.ejmech.2019.111902. PMID 31771828.
- ^ Shintani Y, Hayata-Takano A, Takasaki I, Kurihara T, Miyata A, Yamano Y, et al. (September 2025). "Rapid and long-lasting antidepressant-like effects of the pituitary adenylate cyclase-activating polypeptide receptor antagonist PA-915 in chronic stress mouse models". Molecular Psychiatry. doi:10.1038/s41380-025-03209-4. PMID 40908362.